Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 118 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bacteremia Clear all
Active, not recruiting Not applicable Interventional

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study

NCT03901807
View directory record Official record
Conditions
Septic Shock, Endotoxemia
Interventions
Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
Device
Lead sponsor
Spectral Diagnostics (US) Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 1 Interventional

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

NCT00130221
View directory record Official record
Conditions
Nosocomial Infection, Bacteremia, Sepsis, Pneumonia, Urinary Tract Infection, Clostridium Infection
Interventions
2% chlorhexidine gluconate impregnated cloth, Daily bathing with Bar soap
Drug · Other
Lead sponsor
Cook County Health
Government
Eligibility
16 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 21, 2026, 1:25 PM EDT
Terminated Phase 3 Interventional Results available

Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections

NCT01483872
View directory record Official record
Conditions
Infection; Dialysis Catheter
Interventions
NAC/Tigecycline/Heparin combination lock solution, Standard anticoagulant (Heparin or Citrate)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Jul 21, 2026, 1:25 PM EDT
Completed No phase listed Observational

Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

NCT02420366
View directory record Official record
Conditions
Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia
Interventions
Not listed
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

NCT02439359
View directory record Official record
Conditions
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Interventions
CF-301, Placebo
Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Lenexa, Kansas • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Jul 21, 2026, 1:25 PM EDT
Completed No phase listed Observational

Gram Negative Bacteremia, Risk Factors for Failure of Therapy

NCT00177957
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

NCT00027248
View directory record Official record
Conditions
Sepsis, Bacteremia, Fungemia
Interventions
MBI 226
Drug
Lead sponsor
BioWest Therapeutics Inc
Industry
Eligibility
16 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Lake Bluff, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

NCT00001030
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

NCT03138733
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Ceftobiprole medocaril, Daptomycin
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

NCT00002032
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Irvine, California • Sylmar, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 1:25 PM EDT
Not listed No phase listed Observational

VENOUS: A Translational Study of Enterococcal Bacteremia

NCT04410276
View directory record Official record
Conditions
Enterococcal Bacteremia
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
8
States / cities
Miami, Florida • Detroit, Michigan • Jackson, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Jul 21, 2026, 1:25 PM EDT
Active, not recruiting No phase listed Observational

Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia

NCT05296590
View directory record Official record
Conditions
Bacteremia, Bacteremia Sepsis, Sepsis, Septic Shock, Severe Sepsis, Emergency Departments, Continuity of Patient Care
Interventions
Monocyte Distribution Width (MDW) , observation
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 1:25 PM EDT
Enrolling by invitation Phase 4 Interventional

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

NCT07148960
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 21, 2026, 1:25 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

NCT03148756
View directory record Official record
Conditions
Endocarditis, Bacteremia
Interventions
Dalbavancin, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Ft. Pierce, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 21, 2026, 1:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge

NCT07486362
View directory record Official record
Conditions
Bacteremia
Interventions
No Intervention
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 1:25 PM EDT
Completed No phase listed Observational

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

NCT00414362
View directory record Official record
Conditions
Urinary Tract Infection, Fluoroquinolone, Bacteremia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional

Multicenter Blood Culture Quality Improvement

NCT01413555
View directory record Official record
Conditions
Bacteremia
Interventions
Blood Culture QI Program
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
14,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional

Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)

NCT00235690
View directory record Official record
Conditions
Bacteremia, Pseudomonas Infections
Interventions
Blood draws, Blood draw
Procedure · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Jul 21, 2026, 1:25 PM EDT
Terminated Phase 2 Interventional

CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)

NCT00107666
View directory record Official record
Conditions
Coronary Disease, Heart Valve Diseases
Interventions
CTI-01 (ethyl pyruvate)
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Laguna Hills, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2006 · Synced Jul 21, 2026, 1:25 PM EDT
Terminated Phase 3 Interventional Results available

Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

NCT00108433
View directory record Official record
Conditions
Bacteremia, Gram-Positive Bacterial Infections
Interventions
Cefazolin IV, Linezolid IV, Vancomycin (IV)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Jul 21, 2026, 1:25 PM EDT
Active, not recruiting Not applicable Interventional Results available

Assessing Gut Microbiota Mediated Health Outcomes of Whole Wheat and Its Major Bioactive Components

NCT05318183
View directory record Official record
Conditions
PreDiabetes, Dysbiosis, Endotoxemia, Inflammation
Interventions
Whole Wheat Bread, White Bread (control)
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 21, 2026, 1:25 PM EDT
Completed No phase listed Observational

MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial

NCT00814151
View directory record Official record
Conditions
Bacteremia, Staphylococcal Infection, Sepsis, Infection
Interventions
MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)
Other
Lead sponsor
MicroPhage, Inc.
Industry
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Evanston, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2008 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock

NCT01046669
View directory record Official record
Conditions
Septic Shock, Endotoxemia
Interventions
TORAYMYXIN PMX-20R (PMX cartridge), Standard medical care for septic shock
Device · Other
Lead sponsor
Spectral Diagnostics (US) Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 21, 2026, 1:25 PM EDT
Withdrawn Phase 4 Interventional

Oritavancin for Staphylococcus Aureus Infections in Opioid Users

NCT03761953
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
Oritavancin Injection
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jul 21, 2026, 1:25 PM EDT